Omnaris is NOT indicated for asthma treatment
Omnaris (ciclesonide) nasal spray is FDA-approved exclusively for allergic rhinitis, not asthma. You are asking about the wrong formulation of ciclesonide 1.
Critical Distinction Between Ciclesonide Formulations
There are two separate ciclesonide products with different indications:
Omnaris Nasal Spray: For allergic rhinitis only (seasonal and perennial) - administered intranasally at 200 mcg/day (2 sprays per nostril once daily) 1
Alvesco (ciclesonide HFA inhaler): For asthma - administered via oral inhalation at different doses
Correct Asthma Dosing (Alvesco, NOT Omnaris)
If you're treating asthma with ciclesonide, you need Alvesco metered-dose inhaler, not Omnaris nasal spray. Based on the research evidence:
For Adults and Adolescents ≥12 years:
- Initial dose: 80-160 mcg twice daily (ex-actuator dose)
- Maximum studied dose: 320 mcg twice daily 2, 3
- Once-daily dosing at 80-320 mcg has been shown effective 3
For Children 6-11 years:
- Effective range: 40-160 mcg once daily in the evening 4
- All three doses (40,80,160 mcg) showed efficacy with no dose-response difference in safety 4, 5
For Children 4-5 years:
- Limited evidence; not well-established in this age group 6
Common Pitfall to Avoid
Do not use Omnaris nasal spray for asthma. The intranasal formulation delivers only 50 mcg per actuation to the nasal mucosa 1 and is not designed for pulmonary delivery. Using the wrong formulation will result in treatment failure and uncontrolled asthma.
Clinical Context
While ciclesonide (Alvesco) for asthma has favorable safety characteristics including minimal HPA axis suppression and low oropharyngeal deposition 5, 7, the 2020 NAEPP guidelines recommend low-dose inhaled corticosteroids as controller therapy for persistent asthma in patients ≥12 years 6. The specific choice of ICS should be based on availability, cost, and patient preference, as ciclesonide shows similar efficacy to budesonide and fluticasone at equivalent doses 8.